Citi lowered the firm’s price target on Cytokinetics (CYTK) to $77 from $80 and keeps a Buy rating on the shares. The firm views the company’s Q2 report as largely uneventful.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics Positioned for Success: Strong Financials and Strategic Advancements Drive Buy Rating
- Cytokinetics Reports Q2 2025 Financial Results and Updates
- CYTK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Cytokinetics’ Strong Market Position and Growth Potential Justify Buy Rating
- Cytokinetics assumed with Market Perform from Outperform at Raymond James